The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils
- 1 August 2001
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 108 (2) , 275-280
- https://doi.org/10.1067/mai.2001.116865
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Mode of action and pharmacological selectivity of SDZ ASM 981Clinical and Experimental Dermatology, 2001
- Ascomycins: promising agents for the treatment of inflammatory skin diseasesExpert Opinion on Investigational Drugs, 2000
- Mast cell tryptase as a mediator of hyperresponsiveness in human isolated bronchiClinical and Experimental Allergy, 1999
- Upregulation of TNF-α and IL-3 expression in lesional and uninvolved skin in different types of urticariaJournal of Allergy and Clinical Immunology, 1999
- Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugsArthritis & Rheumatism, 1997
- Anti-Inflammatory Effect of FK-506 on Human Skin Mast CellsJournal of Investigative Dermatology, 1992
- Anti-Inflammatory Effect of Cyclosporin A on Human Skin Mast CellsJournal of Investigative Dermatology, 1992
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexesCell, 1991
- Chemistry and Biology of the Immunophilins and Their Immunosuppressive LigandsScience, 1991
- Human skin tryptase: purification, partial characterization and comparison with human lung tryptaseBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1988